HB2346 amends the Illinois Drug Reuse Opportunity Program Act, which governs the donation, handling, and redistribution of unused drugs. The bill updates definitions used in the program, including terms for donors, recipients, eligible patients, priority patients, and recordkeeping-related entities such as returns processors and reverse distributors. It also clarifies that certain cancer drugs requiring manufacturer registration are excluded from the definition of prescription drug for purposes of the Act.
The bill adds new duties for the Illinois Department of Public Health (IDPH). IDPH must maintain and publish on its website a list of participating pharmacies, educate pharmacies about voluntary participation, develop public-facing educational materials about the program, and collect participant information for an annual report to the General Assembly beginning December 31, 2026. Pharmacy recipients must notify IDPH of participation and report data in a format the Department establishes. The bill also makes recordkeeping changes, including allowing records to be accessed by the Department upon request and requiring compliance with federal nonsalable returns recordkeeping rules when donated drugs are processed for tax or other credits.
In practical terms, the bill expands the administrative framework for Illinois' drug reuse program and increases state oversight and reporting. It affects pharmacies, recipients, donors, and other entities that handle donated medications, while also reinforcing compliance with federal drug-distribution and recordkeeping standards. The measure is focused on program administration rather than changing who may receive medications.
The overall sentiment around the bill appears strongly favorable and noncontroversial. It passed the House 110-0, the Senate 57-0, and House concurrence 115-0, indicating broad bipartisan support. No committee transcript concerns are available, and the unanimous votes suggest the bill was viewed as a technical or public-health-oriented update rather than a contested policy change.
The main points of potential contention, based on the text, are limited to administrative burden and privacy/record-access issues. Pharmacies and other participants may need to comply with new notification, reporting, and record-retention expectations, and the Department is given access to records upon request. However, the bill’s unanimous passage suggests these issues did not generate significant opposition.
HB2346 amends the Illinois Drug Reuse Opportunity Program Act (410 ILCS 715) by revising definitions, recordkeeping requirements, and Department of Public Health responsibilities. It adds a new Section 70 requiring IDPH to publish participating pharmacy information, provide education and public materials, and submit annual reports to the General Assembly, while also requiring pharmacy recipients to notify the Department and report data. The bill also authorizes Department access to records and aligns certain recordkeeping with federal nonsalable returns requirements, affecting pharmacies, recipients, donors, and other drug-handling entities.
The bill’s sentiment is overwhelmingly positive and largely procedural. It passed both chambers and concurrence unanimously, with no recorded dissent in the voting history provided. That pattern suggests broad agreement that the measure supports an existing public-health and medication-reuse program without imposing controversial policy shifts.
No major opposition is evident in the available materials. The only plausible areas of concern are the added reporting and recordkeeping duties for pharmacies and recipients, and the Department’s ability to access records upon request. Those provisions could raise administrative workload or compliance questions, but the unanimous votes indicate these issues were not politically contentious in the legislative process.